The Expression Of PAX2 And Mutant P53 In Endometrial Carcinoma And Its Clinical Significance

OBJECTIVE1.This study was to observe the expression of PAX2 and mutant P53in the endometrial carcinoma, hyperplasia and endometrial tissue toexplore the relationship between the expression of PAX2 or mutant P53and the genesis, clinic pathological parameters of endometrial carcinoma(EC) and to explore the function of PAX2 and mutant P53 in the genesisand development of endometrial carcinoma.2.To explore the dependablity in the expression of PAX2 and mutantP53 amplification in endometrial carcinoma pathology。METHODS Determining the expression of PAX2 and mutant P53by immunihistochemical S-P assay in 40 specimens of EC,20 specimens ofendometrial hyperplasia and 10 specimens of normal endometrial toanalyse the relationship between the expression of PAX2 or mutant p53 andthe type of EC,surgical stage,myometrial invasion or pathological grading.All the patients were not treated by chemotherapy, radio therapy andsexhormone therapy before operation.RESULTS1. The positive immunostaining rate of PAX2 in EC was significantlyhigher than that in endometrial atypical hyperplasia and the positiveimmunostaining rate of PAX2 in endometrial atypical hyperplasia wassignificantly higher than normal endometria. There were significantdifference between the group of carcinoma and the group of atypicalhyperplasia (P＜0.05).It was also significant difference between the groupof atypical hyperplasia and the group of normal (P＜0.05).So did thepositive immunostaining rate of mutant P53.2. PAX2 expression was associated with the histological type of EC being。Less frequentin non-endometrioiden dometrial carcinomas (NEECs,3 out of 9 case) than in ECs (24 out of 31, 77.4%) (P＜0.05)Mutant P53 expression was associated with the histological type ofEC,being More f requentin non-endometrioide ndometrialca rcinomas(NEECs,9 out of 9 case) than in ECs (6 out of 31, 19.4%) (P＜0.05)3. The positive immunostaining rate of PAX2 in surgical stageⅠand ssurgical tageⅡof EC were 62%, 81.8% respectively and there weresignificant difference(P＜0.05). The positive immunostaining rate of mutantP53 in surgical stageⅠand s surgical tageⅡof EC were 31%,54.5%respectively and there were no significant difference(P＞0.05).4. The expression of PAX2 in EC with myometrial invasion washigher than those without myometrial invasion,but there is no obviousdifference can be seen from them.(P＞0.05). The expression of PAX2 inEC with superficial myometrial invasion was higher than those with deepmyometrial invasion,but there is no obvious difference can be seen fromthem.(P＞0.05). The expression of mutant P53 in EC with myometrialinvasion was higher than those without myometrial invasion,but there is noobvious difference can be seen from them.(P＞0.05). The expression ofmutant P53 in EC with deep myometrial invasion was higher than thosewith superficial myometrial invasion,but there is obvious difference can beseen from them. (P＜0.05).5. The positive immunostaining rate of PAX2 in EC was becominghigher with pathological grade (G1,G2 and G3) and there were nosignificant difference between every groups. The positive immunostainingrate of mutant P53 in EC was also becoming higher with pathological grade(G1,G2 and G3) and there were significant difference between G1,G3 andG2, G3.6. With the dates dealed by SPSS 13.0,the expression of pax2 and mutant p53 showed positive relationship with the prognosis of EC.CONCLUSIONThe expression of PAX2 and mutant P53 showed positiverelationship with the prognosis of EC.PAX2, mutant P53 may play a role inthe progress of the endometrial carcinoma.